SCHEMBL2655175

SCHEMBL2655175

CON(C)C(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.54
TSHR P16473 3/20 0.50
MLYCD O95822 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MCHR1 Q99705 1/20 0.47
SIGMAR1 Q99720 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
SRD5A2 P31213 1/20 0.44
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
CXCL12 P48061 1/20 0.43
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097869 0.86 MLYCD (0.45) SLC6A3TSHRMLYCDSMN1; SMN2MCHR1
SCHEMBL8988251 0.86 MLYCD (0.45) SLC6A3MLYCDHPGDSLC6A2SLC6A4
SCHEMBL13724877 0.86 MLYCD (0.45) SLC6A3TSHRMLYCDSMN1; SMN2MCHR1
SCHEMBL1438344 0.85 MLYCD (0.48) SLC6A3TSHRMLYCDHPGDSMN1; SMN2
SCHEMBL31073591 0.85 MLYCD (0.48) SLC6A3TSHRMLYCDHPGDSMN1; SMN2
SCHEMBL256724 0.85 MLYCD (0.44) SLC6A3TSHRMLYCDHPGDSMN1; SMN2
SCHEMBL6988786 0.85 MLYCD (0.44) SLC6A3TSHRMLYCDHPGDSMN1; SMN2
SCHEMBL185480 0.85 MEN1 (0.48) SLC6A3TSHRMLYCDHPGDSMN1; SMN2
SCHEMBL5604944 0.85 CYP1A2 (0.44) SLC6A3TSHRMLYCDCYP1A2CYP3A4
SCHEMBL3706341 0.85 MEN1 (0.58) SLC6A3TSHRMLYCDHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US claimed
US-8772500-B2 TRPV3 modulators ABBVIE INC. (US) 2014-07-08 US disclosed
US-20130131036-A1 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2013-05-23 US disclosed
WO-2013062966-A2 NOVEL TRPV3 MODULATORS ABBVIE INC. (US) 2013-05-02 WO disclosed
US-7649009-B2 N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis MERCK & CO., INC. (US) 2010-01-19 US disclosed
EP-1765335-B1 PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-11-25 EP disclosed
EP-1765335-A4 PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-03-04 EP disclosed
US-7465808-B2 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-16 US disclosed
US-7465808-B2 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-16 US disclosed
US-7465808-B2 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-16 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed
WO-2005005393-A2 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-01-20 WO disclosed
US-20040176601-A1 Benzimisazo[4,5-f]isoquinolinone derivatives MERCK SHARP & DOHME LLC 2004-09-09 US disclosed
EP-1414443-A1 BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES Merck & Co., Inc. (US) 2004-05-06 EP disclosed
US-20040067983-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-08 US disclosed
WO-2003011285-A1 BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES MERCK & CO., INC. (US) 2003-02-13 WO disclosed
EP-0906307-A4 SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2002-05-29 EP disclosed
EP-0906307-A1 SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1999-04-07 EP disclosed
US-5859041-A Substituted imidazoles having cytokine inhibitory activity MERCK & CO., INC. (US) 1999-01-12 US disclosed
WO-1997047618-A1 SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131036-A1 NOVEL TRPV3 MODULATORS TRPV3, TRPV4, TRPV5 SLC6A3 553/4885TSHR 952/4885MLYCD 4848/4885
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R SLC6A3 824/4885TSHR 187/4885MLYCD 2027/4885
US-20040176601-A1 Benzimisazo[4,5-f]isoquinolinone derivatives JAK1, JAK3, JAK2 SLC6A3 4855/4885TSHR 2495/4885MLYCD 1627/4885
US-20040067983-A1 CCK-1 receptor modulators CCKAR, CCKBR, GIPR SLC6A3 2192/4885TSHR 164/4885MLYCD 3545/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R SLC6A3 2793/4885TSHR 146/4885MLYCD 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.